Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 150 versus ULTRAVIST 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 150 versus ULTRAVIST 240.
ULTRAVIST 150 vs ULTRAVIST 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonionic iodinated contrast medium that attenuates X-rays, enhancing vascular and tissue contrast due to iodine content. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Iodinated nonionic contrast agent that attenuates X-rays by increasing the density of iodine atoms, enhancing vascular and tissue contrast during imaging procedures. It does not have intrinsic pharmacological activity.
Intravascular administration: 1-2 mL/kg of ULTRAVIST 150 (150 mg iodine/mL) as a bolus or rapid infusion. Typical adult dose ranges from 50-200 mL depending on procedure and patient weight. Not to exceed 7.5 mL/kg.
IV injection: 1.0-2.0 mL/kg (240 mg I/mL) for CT; total dose not to exceed 250 mL per procedure.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours) in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment)
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-30 hours, necessitating dose adjustment.
Primarily renal (glomerular filtration, >95% of injected dose excreted unchanged in urine within 24 hours; negligible biliary/fecal excretion <2%)
Primarily renal excretion via glomerular filtration; approximately >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Radiographic Contrast Agent (Iodinated Non-Ionic)
Radiographic Contrast Agent (Iodinated Non-Ionic)